Elecated Circulating Vaspin Levels Were Decreased By Rosiglitazone Therapy In T2DM Patients With Poor Glycemic Control On Metformin Alone

Objective To investigate the effects of rosiglitazone therapy on plasmavaspin in type2diabetes patients (T2DM)inadequately controlled onmetformin alone.Methods A total of105subjects,including37subjects with normalglucose tolerance (NGT),37subjects with impaired glucoseregulating(IGR),and31T2DM patients with poor glycemic control onmetformin alone were enrolled in this study.Result Fasting plasma vaspin levels were higher in T2DM patientswith poor glyemic control than that in IGR and NGT groups (1.19±0.74vs.0.46±0.26vs.0.54±0.28ug/L,P﹤0.05).There was no differencebetween IGR and NGT groups. In T2DM patients,fasting plasma vaspinconcentrations were significantly decreased after rosiglizatone therapy for12weeks (1.19±0.74vs.0.91±0.54lg/L,P <0.05), accompanied withsignificant amelioration of insulin sensitivity and glucose control. Plasmavaspin levels were positively associated with the fasting insulin and the homeostasis model assessment of IR (HOMA-IR).Conclusion Plasma vaspin level is higher in T2DM patients with poorglycemic control. And rosiglitazone therapy decreased plasma vaspin levelsthrough glucose and insulin sensitivity regulation.